-
Subject Areas on Research
-
A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).
-
A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study.
-
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
-
A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258).
-
A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
-
A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies.
-
A retrospective study exploring the effects of intramuscular aripiprazole on QTc change in agitated medically ill patients.
-
Adjunctive brexpiprazole for the treatment of major depressive disorder.
-
An open-label pilot study of aripiprazole for male and female veterans with chronic post-traumatic stress disorder who respond suboptimally to antidepressants.
-
Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignant syndrome.
-
Aripiprazole: pharmacology, efficacy, safety and tolerability.
-
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
-
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
-
Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment.
-
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.
-
Chronobiologic parameter changes in patients with major depressive disorder and sleep disturbance treated with adjunctive brexpiprazole: An open-label, flexible-dose, exploratory substudy.
-
Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials.
-
Close the ring to break the cycle: tandem quinolone-alkyne-cyclisation gives access to tricyclic pyrrolo[1,2-a]quinolin-5-ones with potent anti-protozoal activity.
-
Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.
-
Comparison of academic and nonacademic sites in multi-center clinical trials.
-
Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity.
-
Crystal structures of the fungal pathogen Aspergillus fumigatus protein farnesyltransferase complexed with substrates and inhibitors reveal features for antifungal drug design.
-
Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer.
-
Deletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action.
-
Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa.
-
Does the intestinal microflora synthesize pyrroloquinoline quinone?
-
Effects of Adjunctive Brexpiprazole on Sleep Disturbances in Patients With Major Depressive Disorder: An Open-Label, Flexible-Dose, Exploratory Study.
-
Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.
-
Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis.
-
Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
-
Emerging therapeutics for ocular surface disease.
-
Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.
-
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.
-
Functions that Protect Escherichia coli from Tightly Bound DNA-Protein Complexes Created by Mutant EcoRII Methyltransferase.
-
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.
-
Optimum duration of regimens for Helicobacter pylori eradication.
-
PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model.
-
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
-
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
-
Phase II study of Dovitinib in recurrent glioblastoma.
-
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104).
-
Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study.
-
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.
-
Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.
-
Quinolone safety and efficacy more important than potency.
-
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
-
Results of phase 3 of the CATIE schizophrenia trial.
-
Structure-functional selectivity relationship studies of β-arrestin-biased dopamine Dâ‚‚ receptor agonists.
-
Tenofovir alafenamide for HIV infection: is less more?
-
The Aryl Hydrocarbon Receptor: A Mediator and Potential Therapeutic Target for Ocular and Non-Ocular Neurodegenerative Diseases.
-
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.
-
The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors.
-
The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression.
-
The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients.
-
Use of aripiprazole in a patient with multiple sclerosis presenting with paranoid psychosis.
-
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
-
Keywords of People